Access the full text.
Sign up today, get DeepDyve free for 14 days.
( Pfaar O , Wolf H , Klimek L , Schnitker J , Wüstenberg E . Immunologic effect and tolerability of intra‐seasonal subcutaneous immunotherapy with an 8‐day up‐dosing schedule to 10,000 standardized quality‐units: a double‐blind, randomized, placebo‐controlled trial. Clin Ther 2012;34:2072‐2081.23063373)
Pfaar O , Wolf H , Klimek L , Schnitker J , Wüstenberg E . Immunologic effect and tolerability of intra‐seasonal subcutaneous immunotherapy with an 8‐day up‐dosing schedule to 10,000 standardized quality‐units: a double‐blind, randomized, placebo‐controlled trial. Clin Ther 2012;34:2072‐2081.23063373Pfaar O , Wolf H , Klimek L , Schnitker J , Wüstenberg E . Immunologic effect and tolerability of intra‐seasonal subcutaneous immunotherapy with an 8‐day up‐dosing schedule to 10,000 standardized quality‐units: a double‐blind, randomized, placebo‐controlled trial. Clin Ther 2012;34:2072‐2081.23063373, Pfaar O , Wolf H , Klimek L , Schnitker J , Wüstenberg E . Immunologic effect and tolerability of intra‐seasonal subcutaneous immunotherapy with an 8‐day up‐dosing schedule to 10,000 standardized quality‐units: a double‐blind, randomized, placebo‐controlled trial. Clin Ther 2012;34:2072‐2081.23063373
Y. Ohashi, Y. Nakai, A. Tanaka, Y. Kakinoki, Y. Washio, Y. Ohno, K. Yamada, Y. Nasako (1998)
Risk factors for adverse systemic reactions occurring during immunotherapy with standardized Dermatophagoides farinae extracts.Acta oto-laryngologica. Supplementum, 538
M. Mellerup, G. Hahn, L. Poulsen, H. Malling (2000)
Safety of allergen‐specific immunotherapy. Relation between dosage regimen, allergen extract, disease and systemic side‐effects during induction treatmentClinical & Experimental Allergy, 30
(2018)
Lolium perenne peptide immunotherapy is well tolerated and elicits a protective B-cell response in seasonal allergic rhinitis patients
( Kaul S , May S , Lüttkopf D , Vieths S . Regulatory environment for allergen‐specific immunotherapy. Allergy 2011;66:753‐764.21288251)
Kaul S , May S , Lüttkopf D , Vieths S . Regulatory environment for allergen‐specific immunotherapy. Allergy 2011;66:753‐764.21288251Kaul S , May S , Lüttkopf D , Vieths S . Regulatory environment for allergen‐specific immunotherapy. Allergy 2011;66:753‐764.21288251, Kaul S , May S , Lüttkopf D , Vieths S . Regulatory environment for allergen‐specific immunotherapy. Allergy 2011;66:753‐764.21288251
( Astvatsatourov A , Mösges R . Specific characteristics in digital assessment of conjunctival redness. Stud Health Technol Inform 2017;238:181‐184.28679918)
Astvatsatourov A , Mösges R . Specific characteristics in digital assessment of conjunctival redness. Stud Health Technol Inform 2017;238:181‐184.28679918Astvatsatourov A , Mösges R . Specific characteristics in digital assessment of conjunctival redness. Stud Health Technol Inform 2017;238:181‐184.28679918, Astvatsatourov A , Mösges R . Specific characteristics in digital assessment of conjunctival redness. Stud Health Technol Inform 2017;238:181‐184.28679918
( Mellerup MT , Hahn GW , Poulsen LK , Malling H . Safety of allergen‐specific immunotherapy. Relation between dosage regimen, allergen extract, disease and systemic side‐effects during induction treatment. Clin Exp Allergy 2000;30:1423‐1429.10998019)
Mellerup MT , Hahn GW , Poulsen LK , Malling H . Safety of allergen‐specific immunotherapy. Relation between dosage regimen, allergen extract, disease and systemic side‐effects during induction treatment. Clin Exp Allergy 2000;30:1423‐1429.10998019Mellerup MT , Hahn GW , Poulsen LK , Malling H . Safety of allergen‐specific immunotherapy. Relation between dosage regimen, allergen extract, disease and systemic side‐effects during induction treatment. Clin Exp Allergy 2000;30:1423‐1429.10998019, Mellerup MT , Hahn GW , Poulsen LK , Malling H . Safety of allergen‐specific immunotherapy. Relation between dosage regimen, allergen extract, disease and systemic side‐effects during induction treatment. Clin Exp Allergy 2000;30:1423‐1429.10998019
E. Álvarez-Cuesta, J. Bousquet, G. Canonica, S. Durham, H. Malling, E. Valovirta (2006)
Standards for practical allergen‐specific immunotherapyAllergy, 61
L. Klimek, J. Uhlig, R. Mösges, K. Rettig, O. Pfaar (2014)
A high polymerized grass pollen extract is efficacious and safe in a randomized double-blind, placebo-controlled study using a novel up-dosing cluster-protocolAllergy, 69
M. Jutel, Lothar Jaeger, R. Suck, H. Meyer, H. Fiebig, O. Cromwell (2005)
Allergen-specific immunotherapy with recombinant grass pollen allergens.The Journal of allergy and clinical immunology, 116 3
H.-J. Mailing, B. Weeke (1993)
Position Paper: ImmunotherapyAllergy, 48
J Ring, K Brockow, D Duda (2007)
Akuttherapie anaphylaktischer Reaktionen. Leitlinie der Deutschen Gesellschaft für Allergologie und klinische Immunologie (DGAKI), des Ärzteverbandes Deutscher Allergologen (ÄDA), der Gesellschaft für Pädiatrische Allergologie und Umweltmedizin (GPA), 16
( Kruse K , Gerwin E , Eichel A , Shah‐Hosseini K , Mösges R . Conjunctival provocation tests: a predictive factor for patients' seasonal allergic rhinoconjunctivitis symptoms. J Allergy Clin Immunol Pract 2015;3:381‐386.25609338)
Kruse K , Gerwin E , Eichel A , Shah‐Hosseini K , Mösges R . Conjunctival provocation tests: a predictive factor for patients' seasonal allergic rhinoconjunctivitis symptoms. J Allergy Clin Immunol Pract 2015;3:381‐386.25609338Kruse K , Gerwin E , Eichel A , Shah‐Hosseini K , Mösges R . Conjunctival provocation tests: a predictive factor for patients' seasonal allergic rhinoconjunctivitis symptoms. J Allergy Clin Immunol Pract 2015;3:381‐386.25609338, Kruse K , Gerwin E , Eichel A , Shah‐Hosseini K , Mösges R . Conjunctival provocation tests: a predictive factor for patients' seasonal allergic rhinoconjunctivitis symptoms. J Allergy Clin Immunol Pract 2015;3:381‐386.25609338
( Alvarez‐Cuesta E , Bousquet J , Canonica GW , et al. Standards for practical allergen‐specific immunotherapy. Allergy 2006;61(Suppl 82):1‐20.)
Alvarez‐Cuesta E , Bousquet J , Canonica GW , et al. Standards for practical allergen‐specific immunotherapy. Allergy 2006;61(Suppl 82):1‐20.Alvarez‐Cuesta E , Bousquet J , Canonica GW , et al. Standards for practical allergen‐specific immunotherapy. Allergy 2006;61(Suppl 82):1‐20., Alvarez‐Cuesta E , Bousquet J , Canonica GW , et al. Standards for practical allergen‐specific immunotherapy. Allergy 2006;61(Suppl 82):1‐20.
H. Riechelmann, Barbara Epple, Gunther Gropper (2003)
Comparison of Conjunctival and Nasal Provocation Test in Allergic Rhinitis to House Dust MiteInternational Archives of Allergy and Immunology, 130
( Justicia JL , Barasona MJ , Serrano P , Moreno C , Guerra F . Predicting patients at high‐risk of systemic reactions to cluster allergen immunotherapy: a pilot prospective observational study. J Investig Allergol Clin Immunol 2006;17:386‐392.)
Justicia JL , Barasona MJ , Serrano P , Moreno C , Guerra F . Predicting patients at high‐risk of systemic reactions to cluster allergen immunotherapy: a pilot prospective observational study. J Investig Allergol Clin Immunol 2006;17:386‐392.Justicia JL , Barasona MJ , Serrano P , Moreno C , Guerra F . Predicting patients at high‐risk of systemic reactions to cluster allergen immunotherapy: a pilot prospective observational study. J Investig Allergol Clin Immunol 2006;17:386‐392., Justicia JL , Barasona MJ , Serrano P , Moreno C , Guerra F . Predicting patients at high‐risk of systemic reactions to cluster allergen immunotherapy: a pilot prospective observational study. J Investig Allergol Clin Immunol 2006;17:386‐392.
M. Calderón, P. Demoly, R. Wijk, J. Bousquet, A. Sheikh, A. Frew, G. Scadding, C. Bachert, H. Malling, R. Valenta, B. Bilò, A. Nieto, C. Akdis, J. Just, C. Vidal, E. Varga, E. Álvarez-Cuesta, B. Bohle, A. Bufe, W. Canonica, V. Cardona, R. Dahl, A. Didier, S. Durham, P. Eng, M. Fernández-Rivas, L. Jacobsen, M. Jutel, J. Kleine‐Tebbe, L. Klimek, J. Lötvall, Carmen Moreno, R. Mosges, A. Muraro, B. Niggemann, G. Pajno, G. Passalacqua, O. Pfaar, S. Rak, G. Senna, G. Senti, E. Valovirta, M. Hage, J. Virchow, U. Wahn, N. Papadopoulos (2012)
EAACI: A European Declaration on Immunotherapy. Designing the future of allergen specific immunotherapyClinical and Translational Allergy, 2
( Rogala B , Glück J . Risks and benefits of allergen immunotherapy. Expert Opin Drug Saf 2009;8:253‐256.19432555)
Rogala B , Glück J . Risks and benefits of allergen immunotherapy. Expert Opin Drug Saf 2009;8:253‐256.19432555Rogala B , Glück J . Risks and benefits of allergen immunotherapy. Expert Opin Drug Saf 2009;8:253‐256.19432555, Rogala B , Glück J . Risks and benefits of allergen immunotherapy. Expert Opin Drug Saf 2009;8:253‐256.19432555
( Moreno C , De San Pedro BS , Millán C , Panizo C , Martín S , Florido F . Exploratory study of tolerability and immunological effect of a short up‐dosing immunotherapy phase with a standardised allergen extract derived from pollen of Olea europaea. Clin Transl Allergy 2015;5:27.26213608)
Moreno C , De San Pedro BS , Millán C , Panizo C , Martín S , Florido F . Exploratory study of tolerability and immunological effect of a short up‐dosing immunotherapy phase with a standardised allergen extract derived from pollen of Olea europaea. Clin Transl Allergy 2015;5:27.26213608Moreno C , De San Pedro BS , Millán C , Panizo C , Martín S , Florido F . Exploratory study of tolerability and immunological effect of a short up‐dosing immunotherapy phase with a standardised allergen extract derived from pollen of Olea europaea. Clin Transl Allergy 2015;5:27.26213608, Moreno C , De San Pedro BS , Millán C , Panizo C , Martín S , Florido F . Exploratory study of tolerability and immunological effect of a short up‐dosing immunotherapy phase with a standardised allergen extract derived from pollen of Olea europaea. Clin Transl Allergy 2015;5:27.26213608
( Bousquet J , Van Cauwenberge P , Khaltaev N ; Aria Workshop Group ; World Health Organization . Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol 2001;108(5 Suppl):S147‐S334.11707753)
Bousquet J , Van Cauwenberge P , Khaltaev N ; Aria Workshop Group ; World Health Organization . Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol 2001;108(5 Suppl):S147‐S334.11707753Bousquet J , Van Cauwenberge P , Khaltaev N ; Aria Workshop Group ; World Health Organization . Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol 2001;108(5 Suppl):S147‐S334.11707753, Bousquet J , Van Cauwenberge P , Khaltaev N ; Aria Workshop Group ; World Health Organization . Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol 2001;108(5 Suppl):S147‐S334.11707753
M. Shamji, L. Wilcock, P. Wachholz, R. Dearman, I. Kimber, P. Wurtzen, M. Larché, S. Durham, J. Francis (2006)
The IgE-facilitated allergen binding (FAB) assay: validation of a novel flow-cytometric based method for the detection of inhibitory antibody responses.Journal of immunological methods, 317 1-2
(2013)
World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects, 310
J. Kelso (2004)
The rate of systemic reactions to immunotherapy injections is the same whether or not the dose is reduced after a local reaction.Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 92 2
( Patel D , Couroux P , Hickey P , et al. Fel d 1–derived peptide antigen desensitization shows a persistent treatment effect 1 year after the start of dosing: a randomized, placebo‐controlled study. J Allergy Clin Immunol 2013;131:103‐109.22981787)
Patel D , Couroux P , Hickey P , et al. Fel d 1–derived peptide antigen desensitization shows a persistent treatment effect 1 year after the start of dosing: a randomized, placebo‐controlled study. J Allergy Clin Immunol 2013;131:103‐109.22981787Patel D , Couroux P , Hickey P , et al. Fel d 1–derived peptide antigen desensitization shows a persistent treatment effect 1 year after the start of dosing: a randomized, placebo‐controlled study. J Allergy Clin Immunol 2013;131:103‐109.22981787, Patel D , Couroux P , Hickey P , et al. Fel d 1–derived peptide antigen desensitization shows a persistent treatment effect 1 year after the start of dosing: a randomized, placebo‐controlled study. J Allergy Clin Immunol 2013;131:103‐109.22981787
M. Rottem (2010)
[Allergic rhinitis and its impact on asthma].Harefuah, 149 6
( Weber RW . Patterns of pollen cross‐allergenicity. J Allergy Clin Immunol 2003;112:229‐239.12897724)
Weber RW . Patterns of pollen cross‐allergenicity. J Allergy Clin Immunol 2003;112:229‐239.12897724Weber RW . Patterns of pollen cross‐allergenicity. J Allergy Clin Immunol 2003;112:229‐239.12897724, Weber RW . Patterns of pollen cross‐allergenicity. J Allergy Clin Immunol 2003;112:229‐239.12897724
( Calderon MA , Demoly P , Gerth van Wijk R , et al. EAACI: a European Declaration on Immunotherapy. Designing the future of allergen specific immunotherapy. Clin Transl Allergy 2012;2:20.23110958)
Calderon MA , Demoly P , Gerth van Wijk R , et al. EAACI: a European Declaration on Immunotherapy. Designing the future of allergen specific immunotherapy. Clin Transl Allergy 2012;2:20.23110958Calderon MA , Demoly P , Gerth van Wijk R , et al. EAACI: a European Declaration on Immunotherapy. Designing the future of allergen specific immunotherapy. Clin Transl Allergy 2012;2:20.23110958, Calderon MA , Demoly P , Gerth van Wijk R , et al. EAACI: a European Declaration on Immunotherapy. Designing the future of allergen specific immunotherapy. Clin Transl Allergy 2012;2:20.23110958
( Kelso JM . The rate of systemic reactions to immunotherapy injections is the same whether or not the dose is reduced after a local reaction. Ann Allergy Asthma Immunol 2004;92:225‐227.14989390)
Kelso JM . The rate of systemic reactions to immunotherapy injections is the same whether or not the dose is reduced after a local reaction. Ann Allergy Asthma Immunol 2004;92:225‐227.14989390Kelso JM . The rate of systemic reactions to immunotherapy injections is the same whether or not the dose is reduced after a local reaction. Ann Allergy Asthma Immunol 2004;92:225‐227.14989390, Kelso JM . The rate of systemic reactions to immunotherapy injections is the same whether or not the dose is reduced after a local reaction. Ann Allergy Asthma Immunol 2004;92:225‐227.14989390
( Shamji MH , Wilcock LK , Wachholz PA , et al. The IgE‐facilitated allergen binding (FAB) assay: validation of a novel flow‐cytometric based method for the detection of inhibitory antibody responses. J Immunol Methods 2006;317:71‐79.17070537)
Shamji MH , Wilcock LK , Wachholz PA , et al. The IgE‐facilitated allergen binding (FAB) assay: validation of a novel flow‐cytometric based method for the detection of inhibitory antibody responses. J Immunol Methods 2006;317:71‐79.17070537Shamji MH , Wilcock LK , Wachholz PA , et al. The IgE‐facilitated allergen binding (FAB) assay: validation of a novel flow‐cytometric based method for the detection of inhibitory antibody responses. J Immunol Methods 2006;317:71‐79.17070537, Shamji MH , Wilcock LK , Wachholz PA , et al. The IgE‐facilitated allergen binding (FAB) assay: validation of a novel flow‐cytometric based method for the detection of inhibitory antibody responses. J Immunol Methods 2006;317:71‐79.17070537
L. Cox (2017)
Sublingual Immunotherapy for Allergic Rhinitis: Is 2-Year Treatment Sufficient for Long-term Benefit?JAMA, 317 6
S. Kaul, S. May, D. Lüttkopf, S. Vieths (2011)
Regulatory environment for allergen‐specific immunotherapyAllergy, 66
Carmen Moreno, B. Pedro, C. Millán, C. Panizo, Santiago Martín, F. Florido (2015)
Exploratory study of tolerability and immunological effect of a short up-dosing immunotherapy phase with a standardised allergen extract derived from pollen of Olea europaeaClinical and Translational Allergy, 5
B. Rogala, J. Glück (2009)
Risks and benefits of allergen immunotherapyExpert Opinion on Drug Safety, 8
( Dogan S , Astvatsatourov A , Deserno TM , et al. Objectifying the conjunctival provocation test: photography‐based rating and digital analysis. Int Arch Allergy Immunol 2014;163:59‐68.24248100)
Dogan S , Astvatsatourov A , Deserno TM , et al. Objectifying the conjunctival provocation test: photography‐based rating and digital analysis. Int Arch Allergy Immunol 2014;163:59‐68.24248100Dogan S , Astvatsatourov A , Deserno TM , et al. Objectifying the conjunctival provocation test: photography‐based rating and digital analysis. Int Arch Allergy Immunol 2014;163:59‐68.24248100, Dogan S , Astvatsatourov A , Deserno TM , et al. Objectifying the conjunctival provocation test: photography‐based rating and digital analysis. Int Arch Allergy Immunol 2014;163:59‐68.24248100
( Ring J , Brockow K , Duda D , et al. Akuttherapie anaphylaktischer Reaktionen. Leitlinie der Deutschen Gesellschaft für Allergologie und klinische Immunologie (DGAKI), des Ärzteverbandes Deutscher Allergologen (ÄDA), der Gesellschaft für Pädiatrische Allergologie und Umweltmedizin (GPA). Allergo J 2007;16:420‐434.)
Ring J , Brockow K , Duda D , et al. Akuttherapie anaphylaktischer Reaktionen. Leitlinie der Deutschen Gesellschaft für Allergologie und klinische Immunologie (DGAKI), des Ärzteverbandes Deutscher Allergologen (ÄDA), der Gesellschaft für Pädiatrische Allergologie und Umweltmedizin (GPA). Allergo J 2007;16:420‐434.Ring J , Brockow K , Duda D , et al. Akuttherapie anaphylaktischer Reaktionen. Leitlinie der Deutschen Gesellschaft für Allergologie und klinische Immunologie (DGAKI), des Ärzteverbandes Deutscher Allergologen (ÄDA), der Gesellschaft für Pädiatrische Allergologie und Umweltmedizin (GPA). Allergo J 2007;16:420‐434., Ring J , Brockow K , Duda D , et al. Akuttherapie anaphylaktischer Reaktionen. Leitlinie der Deutschen Gesellschaft für Allergologie und klinische Immunologie (DGAKI), des Ärzteverbandes Deutscher Allergologen (ÄDA), der Gesellschaft für Pädiatrische Allergologie und Umweltmedizin (GPA). Allergo J 2007;16:420‐434.
C. Bachert, M. Larché, S. Bonini, G. Canonica, T. Kündig, D. Larenas-Linnemann, D. Ledford, H. Neffen, R. Pawankar, G. Passalacqua (2015)
Allergen immunotherapy on the way to product-based evaluation—a WAO statementThe World Allergy Organization Journal, 8
A. Frew, R. Powell, C. Corrigan, S. Durham (2006)
Efficacy and safety of specific immunotherapy with SQ allergen extract in treatment-resistant seasonal allergic rhinoconjunctivitis.The Journal of allergy and clinical immunology, 117 2
J. Kleine‐Tebbe, Mikkel Walmar, Klaus Bitsch-Jensen, E. Decot, O. Pfaar, D. Rojas, F. Rodríguez (2014)
Negative Clinical Results from a Randomised, Double-Blind, Placebo-Controlled Trial Evaluating the Efficacy of Two Doses of Immunologically Enhanced, Grass Subcutaneous Immunotherapy Despite Dose-Dependent Immunological ResponseClinical Drug Investigation, 34
( World Medical Association . World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA 2013;310:2191‐2194.24141714)
World Medical Association . World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA 2013;310:2191‐2194.24141714World Medical Association . World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA 2013;310:2191‐2194.24141714, World Medical Association . World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA 2013;310:2191‐2194.24141714
Kristian Kruse, Eva Gerwin, A. Eichel, K. Shah-Hosseini, R. Mösges (2015)
Conjunctival provocation tests: a predictive factor for patients' seasonal allergic rhinoconjunctivitis symptoms.The journal of allergy and clinical immunology. In practice, 3 3
( Ahnefeld FW , Barth J , Dick W , et al. [Acute therapy of anaphylactoid reactions. Results of an intradisciplinary consensus conference]. Anaesthesist 1994;3:211‐222. German.)
Ahnefeld FW , Barth J , Dick W , et al. [Acute therapy of anaphylactoid reactions. Results of an intradisciplinary consensus conference]. Anaesthesist 1994;3:211‐222. German.Ahnefeld FW , Barth J , Dick W , et al. [Acute therapy of anaphylactoid reactions. Results of an intradisciplinary consensus conference]. Anaesthesist 1994;3:211‐222. German., Ahnefeld FW , Barth J , Dick W , et al. [Acute therapy of anaphylactoid reactions. Results of an intradisciplinary consensus conference]. Anaesthesist 1994;3:211‐222. German.
( Hansen I , Hörmann K , Stuck BA , Schneider‐Gêne S , Mösges R , Klimek L . [Cluster‐immunotherapy in seasonal allergic rhinitis: safety aspects of induction therapy with depot allergoids (Purethal)]. Laryngorhinootologie 2003;82:558‐563.12915987)
Hansen I , Hörmann K , Stuck BA , Schneider‐Gêne S , Mösges R , Klimek L . [Cluster‐immunotherapy in seasonal allergic rhinitis: safety aspects of induction therapy with depot allergoids (Purethal)]. Laryngorhinootologie 2003;82:558‐563.12915987Hansen I , Hörmann K , Stuck BA , Schneider‐Gêne S , Mösges R , Klimek L . [Cluster‐immunotherapy in seasonal allergic rhinitis: safety aspects of induction therapy with depot allergoids (Purethal)]. Laryngorhinootologie 2003;82:558‐563.12915987, Hansen I , Hörmann K , Stuck BA , Schneider‐Gêne S , Mösges R , Klimek L . [Cluster‐immunotherapy in seasonal allergic rhinitis: safety aspects of induction therapy with depot allergoids (Purethal)]. Laryngorhinootologie 2003;82:558‐563.12915987
( Kleine‐Tebbe J , Walmar M , Bitsch‐Jensen K , et al. Negative clinical results from a randomised, double‐blind, placebo‐controlled trial evaluating the efficacy of two doses of immunologically enhanced, grass subcutaneous immunotherapy despite dose‐dependent immunological response. Clin Drug Investig 2014;34:577‐586.)
Kleine‐Tebbe J , Walmar M , Bitsch‐Jensen K , et al. Negative clinical results from a randomised, double‐blind, placebo‐controlled trial evaluating the efficacy of two doses of immunologically enhanced, grass subcutaneous immunotherapy despite dose‐dependent immunological response. Clin Drug Investig 2014;34:577‐586.Kleine‐Tebbe J , Walmar M , Bitsch‐Jensen K , et al. Negative clinical results from a randomised, double‐blind, placebo‐controlled trial evaluating the efficacy of two doses of immunologically enhanced, grass subcutaneous immunotherapy despite dose‐dependent immunological response. Clin Drug Investig 2014;34:577‐586., Kleine‐Tebbe J , Walmar M , Bitsch‐Jensen K , et al. Negative clinical results from a randomised, double‐blind, placebo‐controlled trial evaluating the efficacy of two doses of immunologically enhanced, grass subcutaneous immunotherapy despite dose‐dependent immunological response. Clin Drug Investig 2014;34:577‐586.
L. Noon (1911)
Prophylactic inoculation against hay fever.International archives of allergy and applied immunology, 4 4
( Riechelmann H , Epple B , Gropper G . Comparison of conjunctival and nasal provocation test in allergic rhinitis to house dust mite. Int Arch Allergy Immunol 2003;130:51‐59.12576735)
Riechelmann H , Epple B , Gropper G . Comparison of conjunctival and nasal provocation test in allergic rhinitis to house dust mite. Int Arch Allergy Immunol 2003;130:51‐59.12576735Riechelmann H , Epple B , Gropper G . Comparison of conjunctival and nasal provocation test in allergic rhinitis to house dust mite. Int Arch Allergy Immunol 2003;130:51‐59.12576735, Riechelmann H , Epple B , Gropper G . Comparison of conjunctival and nasal provocation test in allergic rhinitis to house dust mite. Int Arch Allergy Immunol 2003;130:51‐59.12576735
JL Justicia, M. Barasona, P. Serrano, C. Moreno, F. Guerra (2007)
Predicting patients at high-risk of systemic reactions to cluster allergen immunotherapy: a pilot prospective observational study.Journal of investigational allergology & clinical immunology, 17 6
( Noon L . Prophylactic inoculation against hay fever. Lancet 1911;177:1572‐1573.)
Noon L . Prophylactic inoculation against hay fever. Lancet 1911;177:1572‐1573.Noon L . Prophylactic inoculation against hay fever. Lancet 1911;177:1572‐1573., Noon L . Prophylactic inoculation against hay fever. Lancet 1911;177:1572‐1573.
M. Shamji, J. Ceuppens, C. Bachert, P. Hellings, Gaël Placier, Gaëtan Thirion, N. Bovy, S. Durham, J. Duchateau, T. Legon, S. Pirotton (2018)
Lolium perenne peptides for treatment of grass pollen allergy: A randomized, double-blind, placebo-controlled clinical trial.The Journal of allergy and clinical immunology, 141 1
( Jutel M , Jaeger L , Suck R , Meyer H , Fiebig H , Cromwell O . Allergen‐specific immunotherapy with recombinant grass pollen allergens. J Allergy Clin Immunol 2005;116:608‐613.16159631)
Jutel M , Jaeger L , Suck R , Meyer H , Fiebig H , Cromwell O . Allergen‐specific immunotherapy with recombinant grass pollen allergens. J Allergy Clin Immunol 2005;116:608‐613.16159631Jutel M , Jaeger L , Suck R , Meyer H , Fiebig H , Cromwell O . Allergen‐specific immunotherapy with recombinant grass pollen allergens. J Allergy Clin Immunol 2005;116:608‐613.16159631, Jutel M , Jaeger L , Suck R , Meyer H , Fiebig H , Cromwell O . Allergen‐specific immunotherapy with recombinant grass pollen allergens. J Allergy Clin Immunol 2005;116:608‐613.16159631
( Frew AJ , Powell RJ , Corrigan CJ , Durham SR . Efficacy and safety of specific immunotherapy with SQ allergen extract in treatment‐resistant seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol 2006;117:319‐325.16461133)
Frew AJ , Powell RJ , Corrigan CJ , Durham SR . Efficacy and safety of specific immunotherapy with SQ allergen extract in treatment‐resistant seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol 2006;117:319‐325.16461133Frew AJ , Powell RJ , Corrigan CJ , Durham SR . Efficacy and safety of specific immunotherapy with SQ allergen extract in treatment‐resistant seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol 2006;117:319‐325.16461133, Frew AJ , Powell RJ , Corrigan CJ , Durham SR . Efficacy and safety of specific immunotherapy with SQ allergen extract in treatment‐resistant seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol 2006;117:319‐325.16461133
( Bachert C , Larché M , Bonini S , et al. Allergen immunotherapy on the way to product‐based evaluation–a WAO statement. World Allergy Organ J 2015;8:29.26417398)
Bachert C , Larché M , Bonini S , et al. Allergen immunotherapy on the way to product‐based evaluation–a WAO statement. World Allergy Organ J 2015;8:29.26417398Bachert C , Larché M , Bonini S , et al. Allergen immunotherapy on the way to product‐based evaluation–a WAO statement. World Allergy Organ J 2015;8:29.26417398, Bachert C , Larché M , Bonini S , et al. Allergen immunotherapy on the way to product‐based evaluation–a WAO statement. World Allergy Organ J 2015;8:29.26417398
L. Klimek, P. Schendzielorz, R. Piñol, O. Pfaar (2012)
Specific subcutaneous immunotherapy with recombinant grass pollen allergens: first randomized dose‐ranging safety studyClinical & Experimental Allergy, 42
( Malling HJ , Weeke BE . Position Paper: Immunotherapy. Allergy 1993;48(14 Suppl):9‐35.8342741)
Malling HJ , Weeke BE . Position Paper: Immunotherapy. Allergy 1993;48(14 Suppl):9‐35.8342741Malling HJ , Weeke BE . Position Paper: Immunotherapy. Allergy 1993;48(14 Suppl):9‐35.8342741, Malling HJ , Weeke BE . Position Paper: Immunotherapy. Allergy 1993;48(14 Suppl):9‐35.8342741
( Klimek L , Schendzielorz P , Pinol R , Pfaar O . Specific subcutaneous immunotherapy with recombinant grass pollen allergens: first randomized dose‐ranging safety study. Clin Exp Allergy 2012;42:936‐945.22909165)
Klimek L , Schendzielorz P , Pinol R , Pfaar O . Specific subcutaneous immunotherapy with recombinant grass pollen allergens: first randomized dose‐ranging safety study. Clin Exp Allergy 2012;42:936‐945.22909165Klimek L , Schendzielorz P , Pinol R , Pfaar O . Specific subcutaneous immunotherapy with recombinant grass pollen allergens: first randomized dose‐ranging safety study. Clin Exp Allergy 2012;42:936‐945.22909165, Klimek L , Schendzielorz P , Pinol R , Pfaar O . Specific subcutaneous immunotherapy with recombinant grass pollen allergens: first randomized dose‐ranging safety study. Clin Exp Allergy 2012;42:936‐945.22909165
S. Doğan, A. Astvatsatourov, T. Deserno, F. Bock, K. Shah-Hosseini, A. Michels, R. Mösges (2013)
Objectifying the Conjunctival Provocation Test: Photography-Based Rating and Digital AnalysisInternational Archives of Allergy and Immunology, 163
A. Astvatsatourov, R. Mösges (2017)
Specific Characteristics in Digital Assessment of Conjunctival RednessStudies in health technology and informatics, 238
I. Hansen, K. Hörmann, B. Stuck, S. Schneider-Gêne, R. Mösges, L. Klimek (2003)
[Cluster-immunotherapy in seasonal allergic rhinitis: safety aspects of induction therapy with depot allergoids (Purethal)].Laryngo- rhino- otologie, 82 8
Christiane, Druml, Wolzt, Pleiner (2000)
World Medical Association Declaration of HelsinkiInternational Journal of Pharmaceutical Medicine, 14
J. Bousquet, P. Cauwenberge, N. Khaltaev (2001)
Allergic rhinitis and its impact on asthma.The Journal of allergy and clinical immunology, 108 5 Suppl
F. Ahnefeld, J. Bartholeyns, W. Dick, A. Doenicke, T. Fuchs, H. Gervais, H. Laubenthal, H. Löllgen, W. Lorenz, H. Mehrkens (1994)
[Acute therapy of anaphylactoid reactions. Results of an intradisciplinary consensus conference].Der Anaesthesist, 43 4
D. Patel, P. Couroux, P. Hickey, A. Salapatek, P. Laidler, M. Larché, R. Hafner (2013)
Fel d 1-derived peptide antigen desensitization shows a persistent treatment effect 1 year after the start of dosing: a randomized, placebo-controlled study.The Journal of allergy and clinical immunology, 131 1
O. Pfaar, H. Wolf, L. Klimek, J. Schnitker, E. Wüstenberg (2012)
Immunologic effect and tolerability of intra-seasonal subcutaneous immunotherapy with an 8-day up-dosing schedule to 10,000 standardized quality-units: a double-blind, randomized, placebo-controlled trial.Clinical therapeutics, 34 10
R. Weber (2003)
Patterns of pollen cross-allergenicity.The Journal of allergy and clinical immunology, 112 2
M. Shamji, C. Ljørring, J. Francis, M. Calderón, M. Larché, I. Kimber, A. Frew, H. Ipsen, K. Lund, P. Würtzen, S. Durham (2012)
Functional rather than immunoreactive levels of IgG4 correlate closely with clinical response to grass pollen immunotherapyAllergy, 67
( Aasbjerg K , Backer V , Lund G , et al. Immunological comparison of allergen immunotherapy tablet treatment and subcutaneous immunotherapy against grass allergy. Clin Exp Allergy 2014;44:417‐428.24734285)
Aasbjerg K , Backer V , Lund G , et al. Immunological comparison of allergen immunotherapy tablet treatment and subcutaneous immunotherapy against grass allergy. Clin Exp Allergy 2014;44:417‐428.24734285Aasbjerg K , Backer V , Lund G , et al. Immunological comparison of allergen immunotherapy tablet treatment and subcutaneous immunotherapy against grass allergy. Clin Exp Allergy 2014;44:417‐428.24734285, Aasbjerg K , Backer V , Lund G , et al. Immunological comparison of allergen immunotherapy tablet treatment and subcutaneous immunotherapy against grass allergy. Clin Exp Allergy 2014;44:417‐428.24734285
K. Aasbjerg, V. Backer, G. Lund, J. Holm, N. Nielsen, M. Holse, V. Wagtmann, P. Würtzen (2014)
Immunological comparison of allergen immunotherapy tablet treatment and subcutaneous immunotherapy against grass allergyClinical & Experimental Allergy, 44
F. Spertini, G. DellaCorte, A. Kettner, F. Blay, L. Jacobsen, M. Jutel, M. Worm, V. Charlon, C. Reymond (2016)
Efficacy of 2 months of allergen-specific immunotherapy with Bet v 1-derived contiguous overlapping peptides in patients with allergic rhinoconjunctivitis: Results of a phase IIb study.The Journal of allergy and clinical immunology, 138 1
( Spertini F , DellaCorte G , Kettner A , et al. Efficacy of 2 months of allergen‐specific immunotherapy with Bet v 1–derived contiguous overlapping peptides in patients with allergic rhinoconjunctivitis: results of a phase IIb study. J Allergy Clin Immunol 2016;138:162‐168.27373329)
Spertini F , DellaCorte G , Kettner A , et al. Efficacy of 2 months of allergen‐specific immunotherapy with Bet v 1–derived contiguous overlapping peptides in patients with allergic rhinoconjunctivitis: results of a phase IIb study. J Allergy Clin Immunol 2016;138:162‐168.27373329Spertini F , DellaCorte G , Kettner A , et al. Efficacy of 2 months of allergen‐specific immunotherapy with Bet v 1–derived contiguous overlapping peptides in patients with allergic rhinoconjunctivitis: results of a phase IIb study. J Allergy Clin Immunol 2016;138:162‐168.27373329, Spertini F , DellaCorte G , Kettner A , et al. Efficacy of 2 months of allergen‐specific immunotherapy with Bet v 1–derived contiguous overlapping peptides in patients with allergic rhinoconjunctivitis: results of a phase IIb study. J Allergy Clin Immunol 2016;138:162‐168.27373329
( Ohashi Y , Nakai Y , Tanaka A , et al. Risk factors for adverse systemic reactions occurring during immunotherapy with standardized Dermatophagoides farinae extracts. Acta Otolaryngol Suppl 1998;538:113‐117.9879410)
Ohashi Y , Nakai Y , Tanaka A , et al. Risk factors for adverse systemic reactions occurring during immunotherapy with standardized Dermatophagoides farinae extracts. Acta Otolaryngol Suppl 1998;538:113‐117.9879410Ohashi Y , Nakai Y , Tanaka A , et al. Risk factors for adverse systemic reactions occurring during immunotherapy with standardized Dermatophagoides farinae extracts. Acta Otolaryngol Suppl 1998;538:113‐117.9879410, Ohashi Y , Nakai Y , Tanaka A , et al. Risk factors for adverse systemic reactions occurring during immunotherapy with standardized Dermatophagoides farinae extracts. Acta Otolaryngol Suppl 1998;538:113‐117.9879410
( Cox LS . Sublingual immunotherapy for allergic rhinitis: is 2‐year treatment sufficient for long‐term benefit? JAMA 2017;317:591‐593.28196239)
Cox LS . Sublingual immunotherapy for allergic rhinitis: is 2‐year treatment sufficient for long‐term benefit? JAMA 2017;317:591‐593.28196239Cox LS . Sublingual immunotherapy for allergic rhinitis: is 2‐year treatment sufficient for long‐term benefit? JAMA 2017;317:591‐593.28196239, Cox LS . Sublingual immunotherapy for allergic rhinitis: is 2‐year treatment sufficient for long‐term benefit? JAMA 2017;317:591‐593.28196239
Allergy – Wiley
Published: Jan 1, 2018
Keywords: ; ; ; ;
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.